Newsfeeds - Spark Newswire

1 minute read

Morgan Stanley Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $113

October 27, 7:39 AM

Morgan Stanley analyst Matthew Harrison maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $111 to $113.

BMRN

1 minute read

BioMarin Lays Off 4% Of Its Workforce To ‘Simplify’ The Company

By Vandana Singh

October 7, 10:49 AM

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) will redesign the organization to better focus investments that advance its R&D pipeline, maximize recent commercial launch…

BMRN

1 minute read

BioMarin Says One Participant Diagnosed With Leukemia In Late-Stage Hemophilia Gene Therapy Trial

By Vandana Singh

September 12, 12:50 PM

In an SEC filing, BioMarin Pharmaceutical Inc (NASDAQ:BMRN) said that, in August, a participant in its valoctocogene roxaparvovec (BMN 270)…

BMRN

2 minute read

Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

August 24, 6:53 PM

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene…

AIMD

2 minute read

BioMarin Receives European Commission’s Conditional Marketing Authorization For Gene Therapy Candidate

By Ragothaman Srinivasan

August 24, 5:49 PM

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ: BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A in adult patients.

BMRN

5 minute read

BioMarin Pharmaceutical Says European Commission Has Granted Conditional Marketing Authorization To ROCTAVIAN Gene Therapy

By Michael Horton

August 24, 4:40 PM

Maintains Orphan Drug Designation (ODD) in the EU Providing 10-years of Market Exclusivity Significant Benefit Over Existing Therapies for Patients with Severe Hemophilia A in EU Based on EMA Determination of

BMRN

1 minute read

Piper Sandler Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $128

By Benzinga Newsdesk

August 9, 7:21 AM

Piper Sandler analyst Christopher Raymond maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $125 to $128.

BMRN

1 minute read

Cantor Fitzgerald Initiates Coverage On Biomarin Pharmaceutical with Overweight Rating, Announces Price Target of $110

By Benzinga Newsdesk

July 13, 5:56 AM

Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight rating and announces Price Target of $110.

BMRN

4 minute read

The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma’s Alzheimer’s Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral

By Vandana Singh

June 22, 8:54 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

APLS

2 minute read

BioMarin Announces Favorable Results From Global Phase 2 Study Of VOXZOGO For Injection In Infants And Young Children With Achondroplasia At The Endocrine Society Annual Meeting, ENDO 2022, In Atlanta

By Benzinga Newsdesk

June 13, 12:33 PM

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) presented data at The Endocrine Society Annual Meeting, ENDO 2022, demonstrating the Company's ongoing commitment to understanding the lifetime impact of achondroplasia, the

BMRN